Optimizing Hospitalist GLP-1 Prior Auth Workflows

The Inpatient Challenge of GLP-1 Prior Authorization

Hospitalists frequently manage complex patients who may require initiation or continuation of specialized medications, including GLP-1 receptor agonists, during their inpatient stay or upon discharge. The high volume of GLP-1 PAs, coupled with the need for timely approvals in an acute care setting, adds significant administrative load to teams already managing PAs for post-acute placement, observation vs. inpatient status, and DME for discharge. This often necessitates rapid data retrieval and submission under tight deadlines.

Specific GLP-1 PA Triggers in Hospitalist Practice

In the inpatient environment, GLP-1 prior authorization triggers for hospitalists can arise from several scenarios. These include new prescriptions for T2D management in acutely ill patients, continuation of existing GLP-1 therapies upon admission, or initiation of anti-obesity medications like Ozempic, Wegovy, Mounjaro, or Zepbound as part of discharge planning. Each scenario requires precise documentation of factors such as BMI, A1C, and step therapy adherence, which must be rapidly extracted from the EMR.

Klivira's Automated GLP-1 PA Workflow for Hospitalists

• **Indication Classification:** Klivira identifies T2D versus obesity indication from EMR diagnosis and clinical context, ensuring accurate routing.
• **Per-Payer Obesity-Coverage Routing:** Our policy engine maintains current per-payer obesity benefit status (covered, restricted, not-covered) and routes prior authorizations accordingly, critical for drugs like Wegovy and Zepbound.
• **Step Therapy Documentation Automation:** Klivira pulls metformin trial history, BMI documentation, and comorbidity status from FHIR-enabled EMRs, streamlining common step-therapy requirements.
• **Brand-Specific Routing:** Different GLP-1 products, including Ozempic, Mounjaro, and Saxenda, have unique PA criteria; Klivira applies brand-specific logic to optimize approval rates.
• **Specialty Pharmacy Fulfillment Integration:** Post-approval, Klivira facilitates routing to specialty pharmacies, which is common for many GLP-1 products, ensuring seamless patient transition.
• **Patient-Financial Counseling Integration:** When a payer denies an obesity indication, Klivira surfaces manufacturer copay programs and alternative coverage paths, supporting patient financial well-being.

EMR and Payer Touchpoints for Inpatient GLP-1 Therapies

Hospitalists rely on EMR systems for medication ordering (CPOE), documenting diagnoses (ICD-10), and capturing comprehensive clinical notes. Klivira integrates directly with these EMRs, leveraging standards like SMART on FHIR to extract necessary clinical data for GLP-1 PAs. Payer interactions involve automated X12 278 ePA submissions or direct portal interactions, minimizing manual data entry and accelerating the approval process for inpatient and discharge medications.

Evidence-Based GLP-1 Management and Prior Authorization

Klivira's automation platform incorporates clinical guidelines to ensure prior authorization requests are evidence-grounded. For T2D indications, our logic aligns with established criteria such as the ADA Standards of Care, providing a robust framework for assessing clinical appropriateness. This integration of clinical evidence helps to justify GLP-1 therapies like Trulicity and Victoza, supporting both patient outcomes and PA approval rates.